| [1] |
韦思羽,冯震博.HER-2 基因在乳腺癌研究的进展[J].当代医学,2010,16(15):14-15.
|
| [2] |
李秀翠,顾康生,陈利, 等.胃癌患者血清HER-2/neu ECD 水平与肿瘤组织HER-2/neu 表达的相关性及与临床特征的关系[J].安徽医药,2011,15(6):708-710.
|
| [3] |
Leary AF, Hanna WM, van de Vijver MJ, et al.Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients[J].J Clin Oncol,2009,27(10):1694-1705.
|
| [4] |
Haraid D, Yarden Y.Molecular mechanisms underlying ErbB-2/HER-2 action in breast cancer[J].Oncogene, 2000, 19(53):6102- 6114.
|
| [5] |
Fornier MN, Seidman AD, Schwartz MK, et al.Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate[J].Ann Oncol,2005,16(2):234-239.
|
| [6] |
杨辰,曹颖,魏佳玲,等.乳腺癌患者血清HER-2-ECD、CA15-3、TPS 检测的临床意义[J].标记免疫分析与临床,2010,17(6):371-375.
|
| [7] |
刘春萍,逯翀,田元,等.血清HER-2/neu 胞外域在复发转移性乳腺癌患者解救化疗中的临床意义[J].中华实验外科杂志,2009,26(4):422-424.
|
| [8] |
刘彩云,吴健,杨蔚,等.早期乳腺癌患者手术、化疗后血清HER-2/neu ECD 水平变化[J].中国肿瘤临床,2006,33(13):728-730.
|
| [9] |
Molina R,Augé JM,Escudero JM,et al.Evaluation of tumor markers (HER-2/neu oncoprotein,CEA, and CA 15.3) in patients with locoregional breast cancer:prognostic value[J].Tumor Biol,2010,31(2):171-180.
|
| [10] |
Schippinger W, Dandachi N, Regitnig P, et al.The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer[J].Am J Clin Pathol, 2007,128(10):630-637.
|
| [11] |
Mazouni C, Hall A, Broglio K, et al.Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy[J].Cancer, 2007,109(3):496-501.
|
| [12] |
廖天,陆云飞.乳腺癌患者手术和化疗前后血清HER-2 ECD 水平的变化[J].肿瘤防治研究,2010,37(4):435-437.
|
| [13] |
Willsher PC, Beaver J, Pinder S, et al.Prognostic significance of serum c-erbB-2 protein in breast cancer patients[J].Breast Cancer Res Treat,1996,40(3):251-255.
|
| [14] |
Salvadori B, Pinzani P, Distante V, et al.Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer[J].Clin Chem,2005,51(10):254-256.
|
| [15] |
Quaranta M, Daniele A, Coviello M, et al.C-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation [J].Tumori,2006,92(4):311-317.
|
| [16] |
Molina R, Filella X, Zanon G, et al.Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3)in patients with locoregional breast cancer [J].Anticancer Res, 2003,23(8):1043-1050.
|
| [17] |
Kostler WJ, Steger GG, Soleiman A, et al.Monitoring of serum HER-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer [J].Anticancer Res,2004,24(2):1127-1130.
|
| [18] |
Pallud C, Guinebretiere JM, Guepratte S, et al.Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours[J].Anticancer Res,2005,2(2):1433-1440.
|
| [19] |
Yuan P, Xu BH, Chu DT.Correlation between serum HER-2 oncoprotein and patients with breast cancer[J].Chin Med Sci, 2004,19(3):212-215.
|
| [20] |
Ludovini V, Gori S, Colozza M, et al.Evaluation of serum HER-2 extracellular domain in early breast cancer patients:correlation with clinicopathological parameters and survival [J].Ann Oncol, 2008,19(5): 883-890.
|
| [21] |
Mehta RR, McDermott JH, Hieken TJ, et al.Plasma c-erbB-2 levels in breast cancer patients:Prognostic significance in predicting response to chemotherapy[J].J Clin Oncol,1998,16(7):2409-2416.
|
| [22] |
Sandri MT,Johansson H, Colleoni M, et al.Serum levels of HER-2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma[J].Anticancer Res,2004,9 (24) :1261-1266.
|
| [23] |
Lipton A, Ali SM, Leitzel K, et al.Elevated serum HER-2 /neu level predicts decreased response to hormonetherapy in metastatic breast cancer[J].J Clin Oncol,2002,20(6):1467-1472.
|
| [24] |
Lipton A, Ali SM, Leitzel K, et al.Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen[J].J Clin Oncol, 2003,21(10):1967-1972.
|
| [25] |
Ardavanis A, Kountourakis P, Kyriakou F, et al.Trastuzumab plus paclitaxel or cocetaxel in HER-2-negative/ HER-2 ECD- positive anthracycline-and taxane-refractory advanced breast cancer[J].Oncologist,2008,13(4):361-369.
|
| [26] |
Bethune Volters A, Labroquere M, Guepratte S, et al.Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients[J].Anticancer Res,2004,24(2):1083-1089.
|
| [27] |
Molina R, Jo J, Filella X, et al.C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients[J].Anticancer Res, 1999,19(4):2551-2555.
|
| [28] |
Fehm T, Gebauer G, Jager W.Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients[J].Breast Cancer Res Treat,2002,75(2):97-106.
|
| [29] |
沈镇宙,宋三泰,江泽飞,等.NCCN 乳腺癌临床实践指南(中国版)2010 版[EB/OL].[2011-05-01].http:/ /www.nccn-asia.org/pdf/2010_BreastCancer_Ch.pdf.
|